PubRank
Search
About
Stephen J Mather
Author PubWeight™ 33.12
‹?›
Top papers
Rank
Title
Journal
Year
PubWeight™
‹?›
1
Length-dependent retention of carbon nanotubes in the pleural space of mice initiates sustained inflammation and progressive fibrosis on the parietal pleura.
Am J Pathol
2011
1.65
2
Identification of ZDHHC14 as a novel human tumour suppressor gene.
J Pathol
2014
1.55
3
Filled and glycosylated carbon nanotubes for in vivo radioemitter localization and imaging.
Nat Mater
2010
1.45
4
Retargeting of human T cells to tumor-associated MUC1: the evolution of a chimeric antigen receptor.
J Immunol
2008
1.27
5
An intrapatient comparison of 99mTc-EDDA/HYNIC-TOC with 111In-DTPA-octreotide for diagnosis of somatostatin receptor-expressing tumors.
J Nucl Med
2003
1.18
6
Contrasting effects of sunitinib within in vivo models of metastasis.
Angiogenesis
2012
1.00
7
Targeting of CCK-2 receptor-expressing tumors using a radiolabeled divalent gastrin peptide.
J Nucl Med
2009
0.98
8
Conjugation of chelating agents to proteins and radiolabeling with trivalent metallic isotopes.
Nat Protoc
2006
0.96
9
Cancer-specific transgene expression mediated by systemic injection of nanoparticles.
Cancer Res
2009
0.92
10
Cyclic minigastrin analogues for gastrin receptor scintigraphy with technetium-99m: preclinical evaluation.
J Med Chem
2009
0.91
11
Conjugation of DOTA-like chelating agents to peptides and radiolabeling with trivalent metallic isotopes.
Nat Protoc
2006
0.89
12
99mTc-interleukin-2 and (99m)Tc-HMPAO granulocyte scintigraphy in patients with inactive Crohn's disease.
Eur J Nucl Med Mol Imaging
2003
0.89
13
How do HYNIC-conjugated peptides bind technetium? Insights from LC-MS and stability studies.
Dalton Trans
2007
0.88
14
99mTc-interleukin-2 scintigraphy as a potential tool for evaluating tumor-infiltrating lymphocytes in melanoma lesions: a validation study.
J Nucl Med
2004
0.86
15
High-resolution in vivo imaging of breast cancer by targeting the pro-invasive integrin alphavbeta6.
J Pathol
2010
0.86
16
188Re(CO)3-dipicolylamine-alendronate: a new bisphosphonate conjugate for the radiotherapy of bone metastases.
Bioconjug Chem
2010
0.86
17
Technetium-binding in labelled HYNIC-peptide conjugates: role of coordinating amino acids.
J Inorg Biochem
2009
0.86
18
Flexible targeting of ErbB dimers that drive tumorigenesis by using genetically engineered T cells.
Mol Med
2012
0.84
19
Quantitative Accuracy of Low-Count SPECT Imaging in Phantom and In Vivo Mouse Studies.
Int J Mol Imaging
2011
0.84
20
Synthesis and optimization of the labeling procedure of 99mTc-HYNIC-interleukin-2 for in vivo imaging of activated T lymphocytes.
Mol Imaging Biol
2009
0.83
21
Re: controversies--[Tc(CO)3]+ chemistry: a promising new concept for SPET?
Eur J Nucl Med Mol Imaging
2004
0.81
22
Targeted delivery of cytokine therapy to rheumatoid tissue by a synovial targeting peptide.
Ann Rheum Dis
2012
0.81
23
Insertion of a lysosomal enzyme cleavage site into the sequence of a radiolabeled neuropeptide influences cell trafficking in vitro and in vivo.
Cancer Biother Radiopharm
2010
0.80
24
Formulation development and manufacturing of a gastrin/CCK-2 receptor targeting peptide as an intermediate drug product for a clinical imaging study.
Eur J Pharm Sci
2007
0.80
25
99mTc-HYNIC-Gastrin Peptides: Assisted Coordination of 99mTc by Amino Acid Side Chains Results in Improved Performance Both In Vitro and In Vivo.
J Nucl Med
2009
0.80
26
In vitro and in vivo comparison of DTPA- and DOTA-conjugated antiferritin monoclonal antibody for imaging and therapy of pancreatic cancer.
Nucl Med Biol
2007
0.80
27
Trifluoroacetyl-HYNIC peptides: synthesis and 99mTc radiolabeling.
J Med Chem
2007
0.79
28
Evaluation of a transgenic mouse model for anti-human CEA radioimmunotherapeutics.
J Nucl Med
2002
0.78
29
Synthesis of 99mTc-HYNIC-interleukin-12, a new specific radiopharmaceutical for imaging T lymphocytes.
Eur J Nucl Med Mol Imaging
2006
0.78
30
Generation and characterization of a diabody targeting the αvβ6 integrin.
PLoS One
2013
0.77
31
Preparation and characterization of a DOTA-lysine-biotin conjugate as an effector molecule for pretargeted radionuclide therapy.
Bioconjug Chem
2005
0.77
32
Automated radiolabelling of monoclonal antibodies with the Modular Lab system.
Nucl Med Commun
2010
0.77
33
Radiopeptide internalisation and externalization assays: cell viability and radioligand integrity.
Appl Radiat Isot
2010
0.76
34
Radioiodinated recombinant human TSH: a novel radiopharmaceutical for thyroid cancer metastases detection.
Cancer Biother Radiopharm
2004
0.76
35
Structural guided scaffold phage display libraries as a source of bio-therapeutics.
PLoS One
2013
0.76
36
Pathogen identification by nuclear imaging--almost there?
Eur J Nucl Med Mol Imaging
2012
0.75
37
Radiopharmaceutical clinical trials - dose is more than sieverts and becquerels.
Eur J Nucl Med Mol Imaging
2009
0.75
38
99Tc peptide-peptide nucleic acid probes for imaging oncogene mRNAs in tumours.
Nucl Med Commun
2004
0.75
39
The qualified person in radiopharmacy.
Nucl Med Commun
2010
0.75
40
Regressive DOTA labelling performance with indium-111 and yttrium-90 over a week of use.
Eur J Nucl Med Mol Imaging
2005
0.75
41
Analysis of accumulation of 99mTc-octreotide and 99mTc-EDDA/HYNIC-Tyr3-octreotide in the rat kidneys.
Nucl Med Biol
2004
0.75
42
Investigative clinical studies with radiopharmaceuticals.
Nucl Med Commun
2007
0.75
43
VirRAD-a "virtual" radiopharmacy learning community: your input needed.
Eur J Nucl Med Mol Imaging
2002
0.75
44
Novel preparation and characterization of a trastuzumab-streptavidin conjugate for pre-targeted radionuclide therapy.
Nucl Med Commun
2006
0.75